Harmony Biosciences Holdings Overview
Latest ROE for Harmony Biosciences Holdings: 18.14% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow18.14%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
As of the most recent data, HRMY shows a ROE of 18.14%. That is below the Healthcare sector average of 21.28%. Scroll down for historical charts and peer comparison views.
The Healthcare sector average ROE is about 21.28%. Harmony Biosciences Holdings is at 18.14%, which is lower that average. That is roughly 14.8% below the sector mean. Use the comparison chart on this page to see how HRMY stacks up against individual peers as well.
Check the historical chart to see whether HRMY's ROE is trending up or down. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare Harmony Biosciences Holdings with peers to see if the move is company-specific or sector-wide.
Besides this return on equity page, Stockcircle has Harmony Biosciences Holdings's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect ROE (currently 18.14%) with ownership activity and broader fundamentals.
The Healthcare average ROE is about 21.28%, while HRMY is at 18.14%. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.
